Group 1 - The CRO index experienced a decline, with Aopumai leading the drop at 8.46% [1] - Other companies such as Medisi, Bideli Pharmaceutical, Chengdu Xian Dao, and Tigermed also saw declines of 3.72%, 3.16%, 2.74%, and 2.25% respectively [1]

Core Viewpoint - MediXis experienced a stock price decline of 2.01% on December 1, with a current price of 56.15 CNY per share and a total market capitalization of 7.544 billion CNY [1] Group 1: Stock Performance - Year-to-date, MediXis's stock price has increased by 86.11%, but it has seen a decline of 1.04% over the last five trading days, 19.45% over the last 20 days, and 12.55% over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on July 17, where it recorded a net purchase of 102 million CNY [2] Group 2: Financial Performance - For the period from January to September 2025, MediXis achieved a revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.6849 million CNY, showing a year-on-year increase of 76.93% [2] - Since its A-share listing, MediXis has distributed a total of 158 million CNY in dividends, with 33.9365 million CNY distributed over the past three years [3] Group 3: Company Overview - MediXis, established on February 2, 2004, and listed on November 5, 2019, is located in the Pudong New Area of Shanghai and specializes in providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [2] - The company's main business revenue composition includes 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - MediXis is classified under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, and is associated with concepts such as margin trading, MSCI China, specialized and innovative enterprises, artificial intelligence, and CRO concepts [2]

Group 1 - The core viewpoint of the news is that Shanghai Medicilon Inc. has seen a stock price increase of 5.04%, reaching 59.77 CNY per share, with a total market capitalization of 8.03 billion CNY [1] - Medicilon was established on February 2, 2004, and went public on November 5, 2019, providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes 50.34% from preclinical research, 49.64% from drug discovery and pharmaceutical research, and 0.01% from other supplementary services [1] Group 2 - From the perspective of fund holdings, Wan Jia Fund has one fund heavily invested in Medicilon, specifically the Wan Jia National Index 2000 ETF, which held 99,500 shares, accounting for 0.54% of the fund's net value [2] - The Wan Jia National Index 2000 ETF was established on June 29, 2022, with a latest scale of 1.286 billion CNY and has achieved a year-to-date return of 26.92% [2] - The fund manager, Yang Kun, has a total asset scale of 13.868 billion CNY, with the best fund return during his tenure being 81.38% and the worst being -32.3% [2]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

证券代码：688202 证券简称：美迪西 公告编号：2025-070 上海美迪西生物医药股份有限公司 关于调整公司使用闲置自有资金进行现金管理 投资品种的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据公司经营和资金使用安排，在确保满足公司正常经营活动的资金需求及 风险可控的前提下，为提高资金使用效率和收益，公司于 2025 年 11 月 21 日召 开第四届董事会第九次会议，审议通过《关于调整公司使用闲置自有资金进行现 金管理投资品种的议案》，同意将前述议案中的"购买安全性高、流动性好、具 有合法经营资格的金融机构销售的有保本约定的投资产品（包括但不限于保本型 理财产品、结构性存款、定期存款、通知存款、大额存单等）"调整为"购买安 全性高、流动性好、风险较低（不超过 R2 等级）、具有合法经营资格的金融机 构销售的投资产品（包括但不限于结构性存款、定期存款、通知存款、大额存单、 银行理财产品、券商理财产品、券商收益凭证、货币基金等）"，除上述调整外， 其他原审议事项不变，该事项无需提交股东会审议。现将具体事项公 ...

Core Insights - The oncology CRO (Contract Research Organization) services focus on specialized outsourcing for cancer drug development, addressing challenges such as long R&D cycles, high difficulty, and significant risks, thereby efficiently advancing drugs from preclinical stages to market [1][5][4] - The global oncology CRO services market is projected to grow from $7.2 billion in 2020 to $16.2 billion in 2024, with an expected increase to $18.6 billion by 2025 [1][5] - The oncology CRO sector is a highly specialized segment within the broader CRO market, providing comprehensive or partial outsourcing services for clinical trials of anti-cancer drugs [3][4] Industry Definition and Segmentation - CROs provide professional services to pharmaceutical companies and research institutions throughout the drug development process, covering drug discovery, preclinical research, clinical trials, data management, and regulatory submissions [2][4] - Oncology CRO services include preclinical, clinical, and post-marketing services, with preclinical services further divided into hematological cancers, solid tumors, and others [3][4] Current Industry Status - The CRO industry is experiencing significant growth, reflecting a revitalization of the entire pharmaceutical innovation ecosystem [4][5] - The global CRO services market is expected to expand from $62 billion in 2020 to $98.4 billion in 2024, with China's market growing from $7 billion to $10.5 billion in the same period [5] Industry Value Chain - The upstream of the oncology CRO service industry includes basic chemical raw materials, pharmaceutical intermediates, and various scientific instruments [6] - The midstream consists of oncology CRO service providers, which are the core of the industry chain, characterized by technology and talent intensity [6] - The downstream includes demand-side entities such as pharmaceutical and biotechnology companies, medical institutions, and clinical trial researchers [6] Competitive Landscape - The oncology CRO industry in China features a dynamic and layered competitive landscape, with significant differences in scale, service range, client base, and core competencies among companies [9][10] - Key players in the oncology CRO sector include WuXi AppTec, Kanglong Chemical, and others, with a focus on comprehensive services from target validation to new drug registration [10][11] Development Trends - The oncology CRO service industry reflects the pulse of China's pharmaceutical R&D, transitioning from a traditional labor-intensive service sector to a modern, technology-driven, data-intensive industry [13] - The trend towards intelligent systems in clinical CRO services is seen as an inevitable evolution [13]

Core Viewpoint - Medisi (688202.SH) experienced a significant decline of nearly 9%, reaching a new low of 56.14 yuan, with a total market value of 7.54 billion yuan due to a share reduction announcement by shareholder Chen Guoxing [1] Summary by Relevant Sections - **Share Reduction Announcement** - Shareholder Chen Guoxing plans to reduce holdings by no more than 2.2 million shares, representing up to 1.64% of the company's total share capital [1] - The company has issued share reduction plan announcements four times in the past three years [1] - **Financial Performance** - The company reported third-quarter revenue of 303 million yuan, reflecting a year-on-year growth of 7.94% [1] - The net profit showed a loss of 16.7865 million yuan [1]

Core Viewpoint - MediXis (688202) experienced a significant stock decline of over 8% following the announcement of a planned share reduction by a major shareholder [1] Group 1: Stock Performance - On November 20, MediXis's stock price dropped to 56.55 CNY per share, reflecting a decline of 8.27% [1] Group 2: Shareholder Actions - Shareholder Chen Guoxing intends to reduce his holdings by up to 2.2 million shares, which represents no more than 1.64% of the company's total share capital [1]

Policy Developments - The National Medical Products Administration (NMPA) is focusing on the quality supervision of selected drugs in centralized procurement, emphasizing the importance of quality safety and compliance in production [1] - The NMPA will implement comprehensive production inspections and product sampling for selected drugs, optimizing work mechanisms and exploring risk monitoring [1] - The NMPA acknowledges the development of the medical device industry in Chongqing and stresses the need for a robust quality safety responsibility system [2] Drug and Device Approvals - Baiyunshan's subsidiary Zhongyi Pharmaceutical received a registration certificate for the traditional medicine An Gong Niu Huang Wan from Vietnam's Ministry of Health, aiding market expansion [3] - Huyou Pharmaceutical announced that its subsidiary Seacross Pharmaceuticals Ltd. received marketing approvals for multiple products from regulatory authorities in Pakistan, the UK, and North Macedonia [4] - Zhifei Biological's recombinant herpes zoster vaccine (ZFA01) clinical trial application has been accepted by the NMPA, which may enhance vaccine efficacy [5] Capital Market Activities - Puluo Pharmaceutical plans to repurchase shares worth between RMB 180 million and RMB 360 million, with a maximum price of RMB 23 per share [6][7] - Sinovac Biotech received a delisting notice from NASDAQ due to failure to submit its annual report by the deadline, with potential trading suspension imminent [8] Industry Developments - Researchers published a detailed immune response map following pig kidney transplants in brain-dead patient models, identifying key factors for transplant success [9] - Haizheng Pharmaceutical's subsidiary plans to collaborate with the East China Institute for the biomanufacturing of heparin, with a project budget not exceeding RMB 120 million [10] Public Sentiment Alerts - Guangyuyuan announced the resignation of Vice President Wang Junbo due to work adjustments, effective immediately [11] - Medici's shareholder Chen Guoxing plans to reduce his stake by up to 1.64% through trading methods due to personal financial needs [12]

Core Viewpoint - The announcement details a share reduction plan by shareholder Chen Guoxing of Shanghai Medicy Bio-Pharmaceutical Co., Ltd., indicating a planned reduction of up to 2,200,000 shares, which is 1.64% of the total share capital, due to personal funding needs [3][11]. Shareholder Holdings - As of the announcement date, shareholder Chen Guoxing holds 4,875,154 shares, representing 3.63% of the total share capital, while together with his concert party Lin Changqing, they hold a total of 8,806,324 shares, accounting for 6.55% of the total share capital [2]. Reduction Plan Details - The reduction will be executed through centralized bidding and block trading within three months after the disclosure of the reduction plan, excluding periods when reductions are prohibited by regulations [3][6]. - The reduction price will be determined based on market prices at the time of the reduction, and adjustments will be made if there are changes in share capital due to dividends, stock splits, or other corporate actions [3][11]. Future Holding Intentions - After the completion of the reduction plan, Chen Guoxing intends to continue holding shares in the company and will comply with relevant laws and regulations regarding further reductions based on personal development needs [3][8]. Previous Commitments - Chen Guoxing has made commitments regarding shareholding, including a lock-up period of 36 months post-IPO, restrictions on transferring shares during certain conditions, and a maximum of 25% transfer of shares per year while serving as a director or senior management [7][8].